Published in N Engl J Med on January 01, 2004
Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis (2008) 4.05
Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med (2009) 4.03
Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One (2008) 3.05
HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet (2006) 2.86
Maternal and neonatal herpes simplex virus infections. N Engl J Med (2009) 2.85
Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS One (2015) 2.68
Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet (2012) 2.54
Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa. J Clin Microbiol (2007) 2.42
Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA (2011) 1.85
Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci Transl Med (2009) 1.60
Herpes simplex virus type 2: epidemiology and management options in developing countries. Sex Transm Infect (2006) 1.56
A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med (2009) 1.56
The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection. Sex Transm Infect (2006) 1.56
A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex Transm Infect (2005) 1.54
Serological diagnosis of human herpes simplex virus type 1 and 2 infections by luciferase immunoprecipitation system assay. Clin Vaccine Immunol (2009) 1.46
STI management and control in North America IUSTI region. Sex Transm Infect (2011) 1.38
Interim modelling analysis to validate reported increases in condom use and assess HIV infections averted among female sex workers and clients in southern India following a targeted HIV prevention programme. Sex Transm Infect (2010) 1.38
Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol (2012) 1.36
HSV-2: in pursuit of a vaccine. J Clin Invest (2011) 1.29
Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. J Infect Dis (2006) 1.27
Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol (2006) 1.25
What is the achievable effectiveness of the India AIDS Initiative intervention among female sex workers under target coverage? Model projections from southern India. Sex Transm Infect (2006) 1.24
Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am J Reprod Immunol (2009) 1.24
An intravaginal ring for the simultaneous delivery of multiple drugs. J Pharm Sci (2012) 1.17
Aetiology of sexually transmitted infections and response to syndromic treatment in southwest Uganda. Sex Transm Infect (2005) 1.13
Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine (2005) 1.12
Use of the designation "shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling. Sex Transm Infect (2009) 1.12
Novel approaches in fighting herpes simplex virus infections. Expert Rev Anti Infect Ther (2009) 1.12
Rabbit and mouse models of HSV-1 latency, reactivation, and recurrent eye diseases. J Biomed Biotechnol (2012) 1.09
Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa. Vaccine (2008) 1.08
Sexually transmitted infections among HIV-1-discordant couples. PLoS One (2009) 1.06
In vitro Inactivation of Latent HSV by Targeted Mutagenesis Using an HSV-specific Homing Endonuclease. Mol Ther Nucleic Acids (2014) 1.03
Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future. Epidemiol Rev (2010) 1.02
Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy. J Antimicrob Chemother (2011) 1.01
Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection. Antimicrob Agents Chemother (2008) 1.00
New concepts in understanding genital herpes. Curr Infect Dis Rep (2009) 0.99
Changes in the soluble mucosal immune environment during genital herpes outbreaks. J Acquir Immune Defic Syndr (2012) 0.98
Current status and prospects for development of an HSV vaccine. Vaccine (2013) 0.98
Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses. Clin Exp Immunol (2012) 0.97
Sialic acid on herpes simplex virus type 1 envelope glycoproteins is required for efficient infection of cells. J Virol (2007) 0.95
Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nat Med (2013) 0.95
A double-blind placebo-controlled study to evaluate valacyclovir alone and with aspirin for asymptomatic HSV-1 DNA shedding in human tears and saliva. Invest Ophthalmol Vis Sci (2009) 0.94
Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjects. Clin Vaccine Immunol (2008) 0.93
A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine (2012) 0.93
CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections. Antimicrob Agents Chemother (2011) 0.92
Safety and pharmacokinetics of aciclovir in women following release from a silicone elastomer vaginal ring. J Antimicrob Chemother (2012) 0.91
HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression. FASEB J (2013) 0.90
Addition of a C-terminal cysteine improves the anti-herpes simplex virus activity of a peptide containing the human immunodeficiency virus type 1 TAT protein transduction domain. Antimicrob Agents Chemother (2007) 0.90
Multipurpose prevention technologies: the future of HIV and STI protection. Trends Microbiol (2015) 0.90
Patterns of herpes simplex virus shedding over 1 month and the impact of acyclovir and HIV in HSV-2-seropositive women in Tanzania. Sex Transm Infect (2011) 0.89
Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial. J Infect Dis (2013) 0.89
The diagnosis of genital herpes - beyond culture: An evidence-based guide for the utilization of polymerase chain reaction and herpes simplex virus type-specific serology. Can J Infect Dis Med Microbiol (2007) 0.88
The psychosocial impact of serological herpes simplex type 2 testing in an urban HIV clinic. Sex Transm Infect (2005) 0.88
Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics. Rev Med Virol (2013) 0.88
Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial. J Infect Dis (2015) 0.87
Detection, quantification and genotyping of Herpes Simplex Virus in cervicovaginal secretions by real-time PCR: a cross sectional survey. Virol J (2005) 0.87
Incidence of herpes simplex virus type 2 infections in Africa: a systematic review. Open Forum Infect Dis (2014) 0.87
Genital herpes. Sex Transm Infect (2006) 0.86
Asymptomatic memory CD8+ T cells: from development and regulation to consideration for human vaccines and immunotherapeutics. Hum Vaccin Immunother (2014) 0.85
Sexually transmitted infections and sexual function in relation to male fertility. Korean J Urol (2013) 0.85
The challenge of developing a herpes simplex virus 2 vaccine. Expert Rev Vaccines (2012) 0.85
Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs. J Virol (2013) 0.84
Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding. J R Soc Interface (2014) 0.84
In vivo disruption of latent HSV by designer endonuclease therapy. JCI Insight (2016) 0.83
The effects of daily distress and personality on genital HSV shedding and lesions in a randomized, double-blind, placebo-controlled, crossover trial of acyclovir in HSV-2 seropositive women. Brain Behav Immun (2011) 0.83
Rise in seroprevalence of herpes simplex virus type 1 among highly sexual active homosexual men and an increasing association between herpes simplex virus type 2 and HIV over time (1984-2003). Eur J Epidemiol (2007) 0.83
Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples. Clin Infect Dis (2015) 0.83
Health related quality of life in genital herpes: a pilot comparison of measures. Sex Transm Infect (2005) 0.82
Can we reduce the spread of HIV infection by suppressing herpes simplex virus type 2 infection? F1000 Med Rep (2010) 0.81
How safe is safer sex? High levels of HSV-1 and HSV-2 in female sex workers in London. Epidemiol Infect (2006) 0.81
The acceptance of HSV-testing partners of HSV-2 seronegative pregnant women. Sex Transm Dis (2009) 0.81
Effect of high versus low oral doses of valacyclovir on herpes simplex virus-1 DNA shedding into tears of latently infected rabbits. Invest Ophthalmol Vis Sci (2010) 0.81
Comparison of the vaginal microbial communities in women with recurrent genital HSV receiving acyclovir intravaginal rings. Antiviral Res (2013) 0.81
Non-nucleosidic inhibition of Herpes simplex virus DNA polymerase: mechanistic insights into the anti-herpetic mode of action of herbal drug withaferin A. BMC Bioinformatics (2011) 0.81
Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine (2010) 0.81
Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial. Hum Vaccin Immunother (2013) 0.81
Mucosal treatments for herpes simplex virus: insights on targeted immunoprophylaxis and therapy. Future Microbiol (2010) 0.80
Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding. Clin Microbiol Rev (2016) 0.80
Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease. Med Microbiol Immunol (2014) 0.80
Modelling the interactions between herpes simplex virus type 2 and HIV: implications for the HIV epidemic in southern India. Sex Transm Infect (2010) 0.80
Healthcare seeking and sexual behavior among patients with symptomatic newly acquired genital herpes. Sex Transm Dis (2008) 0.80
Case-crossover analysis of condom use and herpes simplex virus type 2 acquisition. Sex Transm Dis (2012) 0.80
Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa. PLoS One (2015) 0.79
Reducing the transmission of genital herpes. BMJ (2005) 0.79
Genital herpes and its management. BMJ (2007) 0.79
Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir. Drug Des Devel Ther (2016) 0.79
Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop. J Acquir Immune Defic Syndr (2007) 0.79
Once daily valacyclovir for reducing viral shedding in subjects newly diagnosed with genital herpes. Infect Dis Obstet Gynecol (2009) 0.78
Incident HSV-2 infections are common among HIV-1-discordant couples. J Infect Dis (2013) 0.78
Randomized double blind placebo control studies, the "Gold Standard" in intervention based studies. Indian J Sex Transm Dis (2012) 0.78
The impact of brief messages on HSV-2 screening uptake among female defendants in a court setting: a randomized controlled trial utilizing prospect theory. J Health Commun (2014) 0.78
Sexual behaviour and condom use among individuals with a history of symptomatic genital herpes. Sex Transm Infect (2006) 0.77
Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. Clin Transl Med (2016) 0.77
Prevalence and factors associated with herpes simplex virus type 2 infection in patients attending a Baltimore City emergency department. PLoS One (2014) 0.77
Dynasore disrupts trafficking of herpes simplex virus proteins. J Virol (2015) 0.76
Genital herpes. BMJ Clin Evid (2011) 0.76
Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med (2004) 10.31
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 9.17
Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis (2002) 6.99
The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr (2004) 5.94
Use of Bakri balloon tamponade in the treatment of postpartum hemorrhage: a series of 50 cases from a tertiary teaching hospital. Acta Obstet Gynecol Scand (2012) 5.93
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet (2012) 5.82
A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep (2006) 5.63
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med (2011) 5.21
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med (2014) 4.95
Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis (2007) 4.52
Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA (2003) 4.38
Recommendations for the management of herpes zoster. Clin Infect Dis (2007) 4.33
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis (2008) 4.05
Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med (2009) 4.03
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol (2008) 3.95
Genital herpes. Lancet (2007) 3.83
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med (2003) 3.67
Frequent and prolonged shedding of bocavirus in young children attending daycare. J Infect Dis (2010) 3.67
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med (2007) 3.66
Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS (2011) 3.61
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Varicella-zoster virus in the saliva of patients with herpes zoster. J Infect Dis (2008) 3.52
Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med (2014) 3.50
Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis (2004) 3.23
A population-based study of primary human herpesvirus 6 infection. N Engl J Med (2005) 3.07
Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis (2012) 3.06
Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One (2008) 3.05
Risk factors for herpes simplex virus transmission to pregnant women: a couples study. Am J Obstet Gynecol (2005) 2.89
Maternal and neonatal herpes simplex virus infections. N Engl J Med (2009) 2.85
Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol (2002) 2.83
Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis (2008) 2.77
Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med (2012) 2.77
The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis (2004) 2.76
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine (2007) 2.64
Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med (2008) 2.63
Heterosexual anal sex activity in the year after an STD clinic visit. Sex Transm Dis (2008) 2.59
Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis (2012) 2.55
Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet (2012) 2.54
Condom effectiveness for reducing transmission of gonorrhea and chlamydia: the importance of assessing partner infection status. Am J Epidemiol (2004) 2.49
Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One (2010) 2.48
Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. J Infect Dis (2010) 2.45
Genital herpes complicating pregnancy. Obstet Gynecol (2005) 2.45
Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis (2006) 2.43
Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa. J Clin Microbiol (2007) 2.42
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood (2003) 2.41
Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature (2013) 2.38
Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children. Pediatr Blood Cancer (2010) 2.37
Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One (2011) 2.36
Helicase-primase inhibitor pritelivir for HSV-2 infection. N Engl J Med (2014) 2.36
Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS (2007) 2.35
The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med (2005) 2.34
Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus Type 2 infection. J Infect Dis (2007) 2.33
Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis (2008) 2.31
The impact of early monitored management on survival in hospitalized adult Ugandan patients with severe sepsis: a prospective intervention study*. Crit Care Med (2012) 2.29
Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis (2008) 2.27
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol (2007) 2.26
Alcohol use and high-risk sexual behavior among men who have sex with men: the effects of consumption level and partner type. Health Psychol (2004) 2.19
Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis (2007) 2.16
Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clin Infect Dis (2011) 2.15
Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol (2009) 2.13
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Tropical dermatology: fungal tropical diseases. J Am Acad Dermatol (2005) 2.08
Seroprevalence and correlates of herpes simplex virus type 2 infection in five sexually transmitted-disease clinics. J Infect Dis (2002) 2.08
Relative efficacy of prevention counseling with rapid and standard HIV testing: a randomized, controlled trial (RESPECT-2). Sex Transm Dis (2005) 2.03
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol (2011) 2.03
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain (2009) 2.01
Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr (2010) 2.01
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol (2008) 1.99
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res (2010) 1.96
Genital herpes and human immunodeficiency virus: double trouble. Bull World Health Organ (2004) 1.95
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol (2009) 1.94
Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2. Sex Transm Dis (2003) 1.92
Herpes simplex virus type 2 (HSV-2) Western blot confirmatory testing among men testing positive for HSV-2 using the focus enzyme-linked immunosorbent assay in a sexually transmitted disease clinic. Sex Transm Dis (2005) 1.91
Chlamydia trachomatis among patients infected with and treated for Neisseria gonorrhoeae in sexually transmitted disease clinics in the United States. Ann Intern Med (2003) 1.86
Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA (2011) 1.85
Comparison of sexually transmitted disease prevalence by reported level of condom use among patients attending an urban sexually transmitted disease clinic. Sex Transm Dis (2004) 1.82
Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay. J Med Virol (2005) 1.81
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis (2002) 1.80
Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect Dis (2012) 1.80
Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. J Clin Invest (2002) 1.79
Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis (2004) 1.79
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect (2011) 1.78
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol (2009) 1.76
Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol (2011) 1.75